Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Back To School: Catch Up On Our Executive Interviews

This article was originally published in The Pink Sheet Daily

Executive Summary

Recent Q&As explore a range of topics including biomarkers and translational medicine with execs from AstraZeneca, Merck, and Interleukin Genetics; diabetes and FDA's cardiovascular safety guidance; and Millennium Pharmaceuticals' first year as the Takeda Oncology company.

You may also be interested in...



The Medicines Company CEO Clive Meanwell, An Interview With "The Pink Sheet" DAILY (Part 3)

Known as a specialty pharma focused on acquiring abandoned late-stage programs from other companies, TMC now is trying to differentiate itself in the industry with what Meanwell calls the company's "human strategy."

The Medicines Company CEO Clive Meanwell, An Interview With "The Pink Sheet" DAILY (Part 2 Of 3)

The Medicines Company gradually has revised its business model, moving into earlier-stage research, largely through the acquisition of two biotechs in the past year.

The Medicines Company CEO Clive Meanwell, An Interview With "The Pink Sheet" DAILY, (Part 1 Of 3)

While fighting for a patent extension for its sales leader, the specialty pharma has adjusted its business model to include acquisitions and early-stage drug development.

Related Content

Topics

UsernamePublicRestriction

Register

ID1131516

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel